16 material Form 8-K filings that 14 companies we cover made with the SEC in June 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
EUDA Health Holdings said Nasdaq told it on June 13, 2023 that it regained compliance with Listing Rule 5635(c) after CEO Dr. Kelvin Chen agreed to forfeit 271,867 of 850,306 shares issued to him in a loan settlement. Separately, Nasdaq accepted the company's plan to regain compliance with its late-filing rule, provided it files overdue reports by August 4, 2023, or faces possible delisting.
Chen received 850,306 restricted shares at $1.00 each to settle $850,306 in loans; the issue was priced below the $1.47 prior closing bid, which required shareholder approval.
Under a June 8, 2023 Supplemental Agreement, Chen forfeited 271,867 shares, leaving an effective issue price of $1.47 per share.
The company must file its delinquent 10-K and 10-Q by August 4, 2023; failure could lead to a delisting notice and appeal to a Nasdaq Hearings Panel.
Chemomab Therapeutics replaced CEO Dale Pfost and CFO Donald Marvin effective June 1, 2023, reappointing co-founder Adi Mor as CEO and Sigal Fattal as CFO, and named Nissim Darvish Chairman. The company also said it is implementing further cost-reduction measures to extend its cash runway to the end of 2024 and is suspending initiation of a Phase 2 systemic sclerosis trial to preserve capital.
Adi Mor appointed CEO effective June 1, 2023; her compensation will be set later and subject to shareholder approval
Sigal Fattal appointed CFO, replacing Donald Marvin, effective June 1, 2023
Cash runway expected to extend from mid-year 2024 to end of 2024, after the Phase 2 PSC topline data readout expected in the latter part of 2024
Former CEO Dale Pfost will receive 12 months of base salary in cash, accelerated stock option vesting and 12 months of COBRA premiums, subject to a separation agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.